“Multidisciplinary Research Projects on Personalised Medicine – Pre-/Clinical research, Big Data and ICT, Implementation and User’s Perspective”

Deadline for pre-proposal submission is: 5 March 2020 (17:00 CET)

ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 31 funding organisations have agreed to launch the third Joint Transnational Call for research projects in PM. This represents the second of three additional calls non-cofunded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. The available budget for this call is 27 Mio € (approx.).

  • Opening of online submission tool: likely on 16 December 2019

  • Submission deadline for pre-proposals: 5 March 2020 (17:00 CET)

  • Submission deadline for full-proposals: 15 June 2020 (17:00 CEST)

Electronic submission website

Electronic proposal submission is mandatory on PT-Outline. Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on “Sign up” and follow further instructions.

Contact persons for the Joint Call Secretariat (JCS)

The ERA PerMed JCS is hosted by the German Aerospace Center e.V. – Project Management Agency, (DLR-PT):

  • Katja Kuhlmann, Alexandra Becker

  • Heinrich-Konen-Straße 1, 53227 Bonn, GERMANY

  • Tel +49 (0) 228 3821 2211

  • Mail

CALL Documents

The call text and all additional documents can be downloaded below or on the online submission tool:


With its third transnational call (non-cofunded by the EC), ERA PerMed fosters research and innovation activities that build close linkages between basic biomedical research, clinical research, physical sciences, bioengineering, bioinformatics and biostatistics, epidemiology, socio-economic research, as well as research on the integration of PM into clinical practice and on ethical, legal and social implications across the participating countries and beyond. This implies a wide range of multidisciplinary activities brought together by different stakeholders from academia (e.g. universities and research institutions), clinics (e.g. clinical laboratories, medical professionals), industry (e.g. pharmaceutical industry, biotechnology companies, information technology companies including health information technology – HIT), policy makers, regulatory/health technology assessment (HTA) agencies and patients/patient organisations.

The overarching goal is to improve disease prevention and disease management, based on broader and more efficiently characterised and defined patient stratification, diagnostics and tailored treatment protocols. Early involvement of regulatory authorities and close interaction with the different key players along the value chain should be included right from the project development phase to bridge the gap between first discoveries or inventions until market access. Proposals submitted under this call are expected to demonstrate the applicability of project outcomes to clinical practice. The clinical relevance of the proposed PM approach needs to be convincingly demonstrated. Moreover, proposals are expected to include research on ethical, legal and socio-economic implications, including health economics and regulation, and/or research on the optimisation of health care systems. They may also consider patient and citizen empowerment and training strategies for the different stakeholders in PM.

The overall objectives of the call are to:

  • Support translational research projects in the field of Personalised Medicine;

  • Encourage and enable interdisciplinary collaborations towards the implementation of PM, combining pre-clinical and/or clinical research with bioinformatics components and research on relevant ethical, legal and social aspects and/or research on the optimisation of health care systems;

  • Encourage collaboration between academia (research teams from universities, higher education institutions, public research institutions), clinical/public health research (research teams from hospital/ public health, health care settings and other health care organisations), private partners e.g. SMEs[1] (small and medium-sized enterprises) as well as policy makers, regulatory/HTA agencies and patient organisations.


Proposals must be interdisciplinary and clearly demonstrate the potential impact in PM as well as the added value of transnational collaboration.

The JTC2020 of ERA PerMed will comprise three Research Areas:

Each project proposal MUST address at least one module of Research Area 3 and at least one module of Research Area 1 or 2. The coherent integration and combination of the different Research Areas and Modules in the proposals will be part of the evaluation process.


Joint research proposals may be submitted by applicants belonging to one of the following categories (A, B and/or C), if eligible according to their respective regional/national funding organisation’s regulations for research funding:

  1. Academia (research teams working in universities, other higher education institutions) or research institutes;

  2. Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;

  3. (Industry) Private partners, e.g. SMEs[2] (small and medium-size enterprises).

Although proposals will be submitted jointly by research groups from several regions/countries, research groups will be funded by the respective funding organisation of the region/country from which they have applied. Applicants are therefore subject to the eligibility criteria of their respective funding organisations. Applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also “Contact details of participating members”).

  • Only transnational projects will be funded. Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funders participate in the call (see list below). All three legal entities must be independent of each other. At least two partners of the consortium must be from two different EU Member States or Associated Countries.

The coordinator must be eligible to be funded by one of the participating funding organisations to this call. The maximum number of partners per pre-proposal is six. No more than 2 partners from the same country participating in the call will be accepted in one project consortium (including those partners with own funding).

Research groups not eligible for funding (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate if they are able to secure their own funding. They are considered as full partners and have to be integrated in the pre- and full-proposal templates as such. No more than one partner with own funding is allowed in consortia with at least 3 partners that are eligible for funding.

At the full-proposal stage, a consortium might be increased to up to seven partners in total by inclusion of a partner coming from an underrepresented country. A list of underrepresented countries will be provided to all coordinators invited for full-proposals submission.

* minimum 3 partners eligible for funding from three different countries participating to the call

ICPerMed Partnering tool

If you are looking for potential partners, please have a look also at the ICPerMed Partnering Tool:

Contact details of participating members

The following countries (23) are participating in the call: Belgium, Canada, Croatia, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Norway, Panama, Poland, Romania, Slovenia, Spain, Sweden and Turkey.

The following regions (6) are participating in the call: Quebec (Canada), Saxony (Germany), Lombardy (Italy), Tuscany (Italy), Catalonia (Spain) and Navarre (Spain).

The contact list is accessible here.



Comments (28)

  • Shai Linn MD DrPH


    Interested in joining project on personalized medicine. Our expertise – electronic medical record

    Shai Linn, Shay Gueron , University of Haifa, Israel

  • Rita Mano


    Interested in joining consortium for citizen and patient empowerment (Module 3) Expertise in eHealth, mHealth and social media .

  • Raheem Gul


    Interested in developing personalised mathematical models of cardiovascular system in complement with patient data.

  • Ofra Kalter-Leibovici


    Interested in joining a consortium focused in personalized care for people with chronic health conditions (e.g. obesity, diabetes, metabolic syndrome). Expertise in quantitative lifestyle assessment (diet, physical activity), patient education and provision of personalized advice, using our IT tool.

  • Eduard Ling


    Observed complete reversion of familial polyposis (FAP) phenotype in a patient treated with mycophenolate mofetil and tacrolimus. Have an in vitro proof of concept. Intersted in joining consortioum aimed at discovery of IMPDH inhibitors endowed with anti-neoplastic activity.

  • helene


    very nice well done thanks

  • Mehmet Karaoglan


    Interested in joining Clinical Research and Training Strategies for nursing students.
    Our expertise-Advanced Clinical practice, Emergency Nursing and Palliative Care.

  • Mehmet Karaoglan


    “Interested in joining Clinical Research and Training Strategies for nursing students.
    Our expertise-Advanced Clinical practice, Emergency Nursing and Palliative Care.”

  • Esra Acar Soykut


    Intersted in joining consortioum to improve a method by using bacteriphages for personalized medicine

  • Yossi Keshet


    Interested in joining the consortium. My lab expertise is in designing deep learning and machine learning algorithms.

  • Frank Trautwein


    We are interested in joining a consortium for this call. Our expertise: automation of clinical trials management (CTMS) and data collection (PROMs, CRFs, image based endpoints, analyzed with AI), data analysis, interfacing with other systems.

  • M. Murat Civaner


    I am interested in ethical problems related to big data in healthcare and researches. I would like to work on projects aiming to contribute to healthcare provision, research, and policies that are more patient/citizen-centered and respected to civil rights. I do believe that, despite the blinding effect of the shiny and promising developments of AI, we have a responsibility to do the risk/benefit assessments thoroughly, and support individuals to exercise their civil rights as much as we can in a high-tech world, both against the commercial entities and the states…

  • Magdalena Chirila


    We are interested in joining a consortium for this call. Our expertise: clinical research, voice lab

  • Tugce OLGUN


    Looking for two participations to work on the effect of propolis extract of Efe Honey Bee in Turkey on mesenchymal stem cells and patients. We are looking for using propolis on treatment groups, providing mesenchymal stem cell samples, using propolis on treatment groups, or/and the application of propolis on mesenchymal stem cell. Besides, monitoring the effect of propolis on stem cells with imaging data systems could be the other our interest.

  • Hatem Al Khayyal


    I am motivated to help people at the risk for Alzheimer’s disease to reduce their risk.
    Looking for two partners from two different countries for joining a consortium for this call.
    The idea precisely and concisely is to prevent Alzheimer’s dementia by using technology like Mhealth and artificial intelligence to apply a personalized multimodal training approach for people at risk for Alzheimer’s disease.

    Expertise needed: ICT, data management….,



    Alguien que quiera apoyar un proyecto de interoperabilidad sintáctica, ya que aun no llegamos a la semantica en Colombia ?

  • Cristina Bottino


    Interested in joining a consortium to discover novel biomarkers improving diagnosis and therapy in neuroblastoma patients. Our expertise: analysis of cells and plasma exososmes from neuroblastoma patients, flow cytometry, molecular biology, 3D cell culture, immune responses, immune checkpoints, and other tumor escape mechanisms.

  • Hasan Onur Şimşek


    I’m interested in the call. I continue my academic activities as an Oral and Maxillofacial surgeon. I have competence in clinical and preclinical studies in dental field. We are looking for partners who want to be involved in the studies on the detection of anxiety with biometric data.

  • Madara Tirzite


    Seeking for partners interested in field of respiratory medicine, obstructive lung diseases (asthma, COPD, bronchiectatic disease).

  • Christophe Jagla


    I am leading research team working on modeling muscle and heart diseases in a simple model organism, Drosophila. We could contribute to a proposal by modeling (CRISPR genome editing) and assessing pathogenicity (functional analyses) of variant mutations with unknown significance (VUS). We have active collaborations with clinical genetic services and sequencing centers in France. Highly interested by this call.

  • Răzvan Valentin Florian


    We are interested in applying to this field our expertise in artificial intelligence / machine learning / deep learning.

  • Elena Ionica


    Interested in joining the project on personalized medicine. Our expertise – Module 1A Pre-clinical research; cancer and neuromuscular disorders diagnosis, microbiome

  • Adriana Isvoran


    We are interested to join a consortium. Our expertise is in computational studies: prediction of ADME-Tox profiles and pharmacokinetics of potential drugs, molecular docking.

  • Monica Florescu


    Interested in joining the project on personalized medicine. Our expertise – Module 1A Pre-clinical research, Biomarkers detection, Monitoring of biomolecular interaction.

  • Sema Yilmaz


    Cell therapies are getting more important in terms of precision/personalized medicine.
    Cumulus cells are able to be new candidate for anticancer therapy.
    We presented it. (Cumulus Cells Are Potential Candidates for Cell Therapy .in vivo 33: 1921-1927 (2019) doi:10.21873/invivo.11686).
    Trying to investigate not only in solid tumors but also in hematological malignancies such as leukemia.

  • ben azzi


    this is a fantastic blog article.

  • Gambera Laura


    interested in joining a consortium. Our expertise in reproduction medicine and we are interested in biomarkers detection for ovarian aging.

  • Jose Luis Muñoz


    We are interested to join a consortium. Our expertise is related to polymeric nanocarriers for drug delivery (nanocapsules and nanospheres) based on FDA approved polymers, sequential and sustained release in different simulated fluids and metallic nanoparticles functionalized with biomolecules (diagnostic treatment and tracking)

Leave a comment